Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sangamo Biosciences Inc Raises FY 2012 Revenue Guidance
Sangamo Biosciences Inc announced that for fiscal 2012, it expects revenues to be in the range of $18 to $20 million, inclusive of research funding from Shire (earlier guidance was $14 to $18 million). According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $17.63 million for fiscal 2012.
Latest Developments for Sangamo BioSciences Inc
- Sangamo Biosciences Inc Reiterates FY 2013 Revenue Guidance
- Sangamo Biosciences Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
- Sangamo BioSciences, Inc. Reaffirms FY 2012 Revenue Guidance
- Sangamo BioSciences, Inc. Issues FY 2012 Revenue Guidance In Line With Analysts' Estimates
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters